Key result
Subcutaneous insulin sharply and persistently reduces tardive dyskinesia symptom intensity compared to placebo.
Why the study?
Tardive dyskinesia induced by antipsychotic drugs is linked to postsynaptic dopaminergic hypersensitivity driven by energy-dependent receptor synthesis, suggesting glucose availability may influence TD symptoms.
Does low-dose insulin reduce tardive dyskinesia symptoms in chronic schizophrenic outpatients?
RCT (n=20)
Double-blind
Randomly assigned
Does low-dose insulin reduce tardive dyskinesia symptoms in chronic schizophrenic outpatients?
Answers are grounded in this paper and cite their sources.
Low-dose insulin may reduce the intensity of tardive dyskinesia symptoms in chronic schizophrenic patients, possibly by decreasing glucose availability and reversing receptor hypersensitivity.
Tardive dyskinesia (TD) induced by antipsychotic drugs represents a great concern for patients and psychiatrists. Considering its pathophysiological mechanisms, there exists a convergence towards the development of postsynaptic dopaminergic hypersensitivity as a possible cause of TD. Hypersensitivity following receptor blockade is the consequence of an increased number of receptors and such a synthesis is energy-dependent. In the brain, under normal conditions, energy is almost exclusively provided by glucose utilization. We thus hypothesized that, if glucose availability were reduced, the metabolically hyperactive structures should represent the best functional target of a reduction in fuel availability. Twenty chronic schizophrenic outpatients (13 males, 7 females), aged 20-67 (mean: 38.3), accepted to participate in this double-blind, placebo-controlled study. They were randomly assigned to either the insulin treatment group (10 patients) or to the insulin-placebo group (10 patients). They received a subcutaneous injection of 10 units of standard insulin or placebo at 10 a.m. From day 1 to day 15, injections were performed daily and, thereafter, every other week for 5 weeks totalizing 20 injections in 90 days. At day 7, the insulin treatment group showed a sharp decrease in the intensity of TD symptoms which persisted throughout the duration of the study. By contrast, no change in TD symptomatology was observed in the insulin-placebo-treated group. Although a direct effect on DA neurones, or at least the participation of such an effect, cannot be excluded, our data favor a role of decreased glucose availability in reversing receptor hypersensitivity.
No takes yet. Share an insight, caveat, or question.
Mouret et al. (2008) conducted an RCT in Tardive dyskinesia in chronic schizophrenia (n=20). Insulin vs. Placebo was evaluated on Intensity of tardive dyskinesia symptoms. Subcutaneous injection of 10 units of insulin resulted in a sharp, persistent decrease in the intensity of tardive dyskinesia symptoms compared to placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: